drugset / Trial / NCT00207311
Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
Phase 4
Completed
30 enrolled
Brooke Army Medical Center
Hoffmann-La Roche · collabThe Geneva Foundation · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a prospective, multi-center, randomized, placebo-controlled trial in subjects with histological evidence of \> 33% hepatic steatosis or nonalcoholic steatohepatitis (NASH) and chronic hepatitis C. Patients who have not been previously treated for hepatitis C (treatment naive) will be enrolled.
Timeline
- Start
- 2005-08
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Orlistat | Small molecule | 120 mg | — |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
| Comparator | Ribavirin | Small molecule | 800 mg | — |